Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Ban

Showing results (231-240 of 362) with videos related to

Pageof 37
Sort By:
The Journal of Clinical Pharmacology and New Drugs|July 1, 1971
Pentylenetetrazol in the treatment of geriatric patients with disturbed memory functionJ Leckman, J V Ananth, T A Ban, et al.
Canadian Psychiatric Association Journal|February 1, 1970
The place of thiothixene in the treatment of schizophrenic patients. A systematic clinical studyC Sterlin, T A Ban, H E Lehmann, et al.
Journal of Clinical Psychopharmacology|December 10, 1999
International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disordersE H Uhlenhuth, M B Balter, T A Ban, et al.
Depression and Anxiety|June 5, 1999
International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997E H Uhlenhuth, M B Balter, T A Ban, et al.
Journal of Clinical Psychopharmacology|January 1, 1999
International Study of Expert Judgement on Therapeutic Use of Benzodiazepines and Other Psychotherapeutic Medications: V. Treatment strategies in panic disorder, 1992-1997E H Uhlenhuth, M B Balter, T A Ban, et al.
Current Therapeutic Research, Clinical and Experimental|April 1, 1976
A double-blind comparative clinical trial with maprotiline (Ludiomil) and imipramine in newly-admitted depressed patientsH E Lehmann, J C Pecknold, T A Ban, et al.
Internationale Zeitschrift Fur Klinische Pharmakologie, Therapie, Und Toxikologie. International Journal of Clinical Pharmacology, Therapy, and Toxicology|February 1, 1971
Fluphenazine enanthate in the treatment of chronic psychotic patients: a controlled clinical studyR Deverteuil, H E Lehmann, T A Ban, et al.
Psychopharmacology Bulletin|January 1, 1995
International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: III. Clinical features affecting experts' therapeutic recommendations in anxiety disordersE H Uhlenhuth, M B Balter, T A Ban, et al.
Canadian Psychiatric Association Journal|February 1, 1970
Nicotinic acid in the prevention and treatment of methionine-induced exacerbation of psychopathology in schizophrenicsJ V Ananth, T A Ban, H E Lehmann, et al.
Current Therapeutic Research, Clinical and Experimental|April 1, 1970
CI-601, a butyrophenone derivative, in the treatment of chronically withdrawn schizophrenic patientsC Villeneuve, J V Ananth, T A Ban, et al.
Pageof 37

Showing results (231-240 of 362) with videos related to

Sort By:
Pageof 37
The Journal of Clinical Pharmacology and New Drugs|July 1, 1971
Pentylenetetrazol in the treatment of geriatric patients with disturbed memory functionJ Leckman, J V Ananth, T A Ban, et al.
Canadian Psychiatric Association Journal|February 1, 1970
The place of thiothixene in the treatment of schizophrenic patients. A systematic clinical studyC Sterlin, T A Ban, H E Lehmann, et al.
Journal of Clinical Psychopharmacology|December 10, 1999
International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the long-term treatment of anxiety disordersE H Uhlenhuth, M B Balter, T A Ban, et al.
Depression and Anxiety|June 5, 1999
International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992-1997E H Uhlenhuth, M B Balter, T A Ban, et al.
Journal of Clinical Psychopharmacology|January 1, 1999
International Study of Expert Judgement on Therapeutic Use of Benzodiazepines and Other Psychotherapeutic Medications: V. Treatment strategies in panic disorder, 1992-1997E H Uhlenhuth, M B Balter, T A Ban, et al.
Current Therapeutic Research, Clinical and Experimental|April 1, 1976
A double-blind comparative clinical trial with maprotiline (Ludiomil) and imipramine in newly-admitted depressed patientsH E Lehmann, J C Pecknold, T A Ban, et al.
Internationale Zeitschrift Fur Klinische Pharmakologie, Therapie, Und Toxikologie. International Journal of Clinical Pharmacology, Therapy, and Toxicology|February 1, 1971
Fluphenazine enanthate in the treatment of chronic psychotic patients: a controlled clinical studyR Deverteuil, H E Lehmann, T A Ban, et al.
Psychopharmacology Bulletin|January 1, 1995
International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: III. Clinical features affecting experts' therapeutic recommendations in anxiety disordersE H Uhlenhuth, M B Balter, T A Ban, et al.
Canadian Psychiatric Association Journal|February 1, 1970
Nicotinic acid in the prevention and treatment of methionine-induced exacerbation of psychopathology in schizophrenicsJ V Ananth, T A Ban, H E Lehmann, et al.
Current Therapeutic Research, Clinical and Experimental|April 1, 1970
CI-601, a butyrophenone derivative, in the treatment of chronically withdrawn schizophrenic patientsC Villeneuve, J V Ananth, T A Ban, et al.
Pageof 37